ArticleDiabetes care2025
Longitudinal Continuous Glucose Monitoring Study in Young Children With Presymptomatic Type 1 Diabetes Followed in the Environmental Determinants of Islet Autoimmunity (ENDIA) At-Risk Cohort Study.
Article in Diabetes care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Equity, Diversity and Inclusion is essential for rigorous science and good for health.Diabetologia · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectiveTo characterize longitudinal continuous glucose monitoring (CGM) data in young children with presymptomatic type 1 diabetes. RESEARCH DESIGN AND
methodsBetween 2021 and 2024, children in the Australian ENDIA study with persistent multiple islet autoimmunity underwent blinded CGM assessments every 3-6 months. CGM-derived metrics (SD sensor glucose, coefficient of variation, mean sensor glucose, and percent CGM time >7.8 mmol/L [140 mg/dL]) were determined for each child by time from islet autoantibody detection.
resultsA total of 178 CGM assessments were analyzed for 36 children (median [Q1, Q3] age at first assessment 4.5 [3.5, 6.0] years) who underwent a median of 5.5 (2.0, 7.0) assessments of 11 (9, 15) days duration each. High within-person variability was observed in serial CGM metrics, including percent CGM time >7.8 mmol/L (140 mg/dL) (intraclass correlation coefficient 0.30).
conclusionsFurther research is needed to inform interpretation of CGM-derived metrics in young children with presymptomatic type 1 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.